Biggest changeThe following table sets forth our consolidated results of operations for the periods indicated: Years Ended December 31, 2024 2023 Variance % Change (In thousands, except for per share amounts) Total revenue $ 49,592 $ 62,631 $ (13,039) (21) % Cost of revenues (exclusive of depreciation shown below) 25,970 44,979 (19,009) (42) % Operating expenses: Research and development 77,007 68,142 8,865 13 % Depreciation expense 5,567 5,452 115 2 % Selling, general and administrative expense 49,981 50,438 (457) (1) % Total operating expenses $ 132,555 $ 124,032 8,523 7 % Loss from operations (108,933) (106,380) (2,553) 2 % Other income (expense): Interest income, net 3,162 4,572 (1,410) (31) % Other expense, net (17,726) (29,388) 11,662 (40) % Total other expense, net (14,564) (24,816) 10,252 (41) % Loss before income taxes (123,497) (131,196) 7,699 (6) % Loss from equity method investees, net (14,234) $ (2,902) (11,332) 390 % Net loss $ (137,731) $ (134,098) $ (3,633) 3 % Other comprehensive loss: Changes in credit risk of fair value instruments (1,096) — (1,096) nm Foreign currency translation adjustments 124 (376) 500 (133) % Comprehensive loss $ (138,703) $ (134,474) $ (4,229) 3 % Net loss per share - basic and diluted $ (0.70) (0.79) Weighted-average number of common shares outstanding - basic and diluted 197,579,945 176,023,219 Revenue Total revenue decreased $13.0 million, or 21%, in the year ended December 31, 2024, compared to the prior year.
Biggest changeSee “ Non-GAAP Financial Measures ” for additional information and reconciliation of Adjusted EBITDA to net loss, its most directly comparable GAAP measure. 67 Results of Operations The following table sets forth our consolidated results of operations for the periods indicated: Years Ended December 31, 2025 2024 Variance % Change (In thousands, except for per share amounts) Total revenue $ 55,845 $ 49,592 $ 6,253 12.6 % Cost of revenues 1 30,544 25,970 4,574 17.6 % Operating expenses: Research and development 53,184 77,007 (23,823) (30.9) % Depreciation expense 4,227 5,567 (1,340) (24.1) % Selling, general and administrative expense 47,046 49,981 (2,935) (5.9) % Total operating expenses $ 104,457 $ 132,555 $ (28,098) (21.2) % Loss from operations (79,156) (108,933) 29,777 27.3 % Other income (expense): Interest income, net 1,214 3,162 (1,948) (61.6) % Other income (expense), net 41,539 (17,726) 59,265 334.3 % Total other income (expense), net 42,753 (14,564) 57,317 393.6 % Loss before income taxes (36,403) (123,497) 87,094 70.5 % Loss from equity method investees, net (12,548) (14,234) 1,686 11.8 % Net loss $ (48,951) $ (137,731) $ 88,780 64.5 % Other comprehensive loss: Changes in credit risk of fair value instruments 1,091 (1,096) 2,187 (199.5) % Foreign currency translation adjustments (1,040) 124 (1,164) (938.7) % Comprehensive loss $ (48,900) $ (138,703) $ 89,803 64.7 % (1) exclusive of depreciation Revenue Total revenue increased $6.3 million, or 12.6%, in the year ended December 31, 2025, compared to the same period in the prior year.
For example, Adjusted EBITDA: (i) excludes stock-based compensation expense because it is a significant non-cash expense that is not directly related to our operating performance; (ii) excludes depreciation expense and, although this is a non-cash expense, the assets being depreciated and amortized 71 may have to be replaced in the future; (iii) excludes gain or losses on equity method investee; and (iv) excludes certain income or expense items that do not provide a comparable measure of our business performance.
For example, Adjusted EBITDA: (i) excludes stock-based compensation expense because it is a significant non-cash expense that is not directly related to our operating performance; (ii) excludes depreciation expense and, although this is a non-cash expense, the assets being depreciated and amortized may have to be replaced in the future; (iii) excludes gain or losses on equity method investee; and (iv) excludes certain income or expense items that do not provide a comparable measure of our business performance.
We have also developed the capabilities to produce single cell protein as a primary product from our gas fermentation platform. LanzaTech employs a licensing business model whereby our customers build, own and operate facilities that use our technology, and in return, we are paid a royalty fee based on the revenue generated from the use of our technology.
We have also developed the capabilities to produce single cell protein as a primary product from our gas fermentation platform. LanzaTech employs a licensing business model whereby our customers build, own and operate facilities that use our technology, and in return, we are paid a royalty fee based on the revenue generated from the use of 62 our technology.
While our significant accounting policies are more fully described in Note 2 to our consolidated financial statements, we believe that the accounting policies discussed below are critical to understanding our historical and future performance: Revenue Recognition 69 We recognize revenue from our contracts with customers in accordance with ASC 606.
While our significant accounting policies are more fully described in Note 2 to our consolidated financial statements, we believe that the accounting policies discussed below are critical to understanding our historical and future performance: Revenue Recognition We recognize revenue from our contracts with customers in accordance with ASC 606.
Overview We are a nature-based carbon refining company that develops technology to transform waste carbon into the chemical building blocks for consumer goods such as sustainable fuels, fabrics, and packaging that people use in their daily lives.
Overview We are a nature-based carbon refining company that develops technology to transform waste carbon into the chemical building blocks for consumer goods such as fuels, fabrics, and packaging that people use in their daily lives.
We exercise judgment when determining the percentage of completion against the total transaction price initially estimated. For arrangements with government agencies, we measure the satisfaction of performance obligations over time using the input method which requires judgment when selecting the most indicative measure of such performance.
We exercise judgment when determining the percentage of completion against the total transaction price initially estimated. For 72 arrangements with government agencies, we measure the satisfaction of performance obligations over time using the input method which requires judgment when selecting the most indicative measure of such performance.
We have historically funded our operations through the Business Combination, issuances of equity securities, debt financing, as well as from revenue generating activities with commercial and governmental entities.
We have 70 historically funded our operations through the Business Combination, issuances of equity securities, debt financing, as well as from revenue generating activities with commercial and governmental entities.
In accordance with Accounting Standards Update ("ASU") No. 2014-15, “Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern (Subtopic 205-40),” management has evaluated in aggregate the conditions and events that raise substantial doubt regarding the Company’s ability to continue as a going concern through the next twelve months from the date of issuance of the consolidated financial statements for the year ended December 31, 2024 included in this Annual Report and has determined that the Company’s ability to continue as a going concern is dependent on its ability to execute its business plan, raise significant amounts of additional capital and/or implement other strategic options.
In accordance with Accounting Standards Update ("ASU") No. 2014-15, “Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern (Subtopic 205-40),” management has evaluated in aggregate the conditions and events that raise substantial doubt regarding the Company’s ability to continue as a going concern through the next twelve months from the date of issuance of the consolidated financial statements for the year ended December 31, 2025 included in this Annual Report and has determined that the Company’s ability to continue as a going concern is dependent on its ability to raise significant amounts of additional capital, implement other strategic options, and execute its business plan.
Brookfield SAFE Valuation Under the Brookfield SAFE, we agreed to issue to Brookfield the right to certain shares of Legacy LanzaTech’s capital stock, in exchange for the payment of $50.0 million. The Brookfield SAFE was classified as a liability on our consolidated balance sheets as of December 31, 2024 and 2023.
Brookfield SAFE Valuation Under the Brookfield SAFE, we agreed to issue to Brookfield the right to certain shares of Legacy LanzaTech’s capital stock, in exchange for the payment of $50.0 million. The Brookfield SAFE was classified as a liability on our consolidated balance sheets as of December 31, 2024.
(3) Consists of cost of revenues from contracts with customers and grants (exclusive of depreciation), cost of revenue from collaboration agreements (exclusive of depreciation) and cost of revenue from related party transactions (exclusive of depreciation).
(3) Consists of cost of revenues from contracts with customers and grants (exclusive of depreciation), cost of revenues from collaboration agreements (exclusive of depreciation) and cost of revenues from related party transactions (exclusive of depreciation).
Our customers leverage our proven proprietary gas fermentation technology platform to convert certain feedstock, including waste carbon gases, into sustainable fuels and chemicals such as ethanol. Today, we are focused on taking advantage of the many uses of ethanol while capitalizing on the growing preference among major companies for renewable products and environmentally-conscious manufacturing processes.
Our customers leverage our proven proprietary gas fermentation technology platform to convert certain feedstocks, including waste carbon gases, into fuels and chemicals such as ethanol. Today, we are focused on taking advantage of the many uses of ethanol while capitalizing on the growing preference among major companies for renewable products and environmentally-conscious manufacturing processes.
Recently, the Company and LanzaJet launched CirculAir™, a new joint offering and end-to-end solution utilizing LanzaTech’s gas fermentation technology in conjunction with LanzaJet’s Alcohol-to-Jet (“ATJ”) platform to produce sustainable aviation fuel and renewable diesel from a wide range of waste feedstocks. We have not achieved operating profitability since our formation.
In June 2024, the Company and LanzaJet launched CirculAir™, a new joint offering and end-to-end solution utilizing LanzaTech’s gas fermentation technology in conjunction with LanzaJet’s Alcohol-to-Jet (“ATJ”) platform to produce sustainable aviation fuel and renewable diesel from a wide range of waste feedstocks. We have not achieved operating profitability since our formation.
These conditions and events raise substantial doubt about the Company’s ability to continue as a going concern. We are focusing on streamlining our business priorities, taking actions to reduce our cost structure and evaluating other liquidity enhancing initiatives, including pursuing capital raising, partnership or asset-related opportunities, and other strategic options.
These conditions and events raise substantial doubt about the Company’s ability to continue as a going concern. The Company is focusing on streamlining its business priorities, taking actions to reduce its cost structure and evaluating other liquidity enhancing initiatives, including pursuing capital raising, partnership or asset-related opportunities, and other strategic options.
We anticipate that we will continue to incur losses until we sufficiently commercialize our technology. Recent Developments As previously announced, LanzaTech is focused on shifting its core operations from research and development to globally deploying the Company’s proven technology.
We anticipate that we will continue to incur losses until we sufficiently commercialize our technology. LanzaTech is focused on shifting its core operations from research and development to globally deploying the Company’s proven technology.
Convertible Note The Company has elected to measure the Convertible Note using the fair value option under ASC 825. The fair value of the Convertible Note is remeasured at each reporting date using a binomial lattice model.
Convertible Note The Company had elected to measure the Convertible Note using the fair value option under ASC 825. The fair value of the Convertible Note was remeasured at each reporting date using a binomial lattice model.
The Company elected to record the instrument using the fair value option under ASC 825. The Brookfield SAFE was terminated on February 14, 2025. Refer to Note 19 - Subsequent Events in our consolidated financial statements for further information.
The Company elected to record the instrument using the Fair Value Option (“FVO”) under ASC 825. The Brookfield SAFE was terminated on February 14, 2025. Refer to Note 6 — Brookfield Instruments in our consolidated financial statements for further information.
As of December 31, 2024, our capital structure consisted of equity (comprising issued capital, and accumulated deficit), the Brookfield SAFE and the Convertible Note. We are not subject to any externally imposed capital requirements.
As of December 31, 2025, our capital structure consisted of equity (comprising issued capital, and accumulated deficit), and the Brookfield Loan. We are not subject to any externally imposed capital requirements.
In this section, unless otherwise indicated or the context otherwise requires, references in this section to “LanzaTech,” the “Company,” “we,” “us,” “our” and other similar terms refer to LanzaTech Global, Inc. and its consolidated subsidiaries, including LanzaTech NZ, Inc. and its consolidated subsidiaries subsequent to the Business Combination and LanzaTech NZ, Inc. and its consolidated subsidiaries prior to the Business Combination.
In this section, unless otherwise indicated or the context otherwise requires, references in this section to “LanzaTech,” the “Company,” “we,” “us,” “our” and other similar terms refer to LanzaTech Global, Inc. and its consolidated subsidiaries. References to “AMCI” refer to AMCI Acquisition Corp. II prior to the Business Combination.
In light of the our projected capital expenditures and operating requirements under our current business plan, we are projecting that our existing cash and short-term held-to-maturity debt securities will not be sufficient to fund our operations through the next twelve months from the date of issuance of the consolidated financial statements for the year ended December 31, 2024 included in this Annual Report.
In light of the Company’s operating requirements and projected capital expenditure under its current business plan, the Company is projecting that its existing cash and short-term debt securities will not be sufficient to fund its operations through the next twelve months from the date of issuance of the consolidated financial statements for the year ended December 31, 2025 included in this Annual Report.
Our ability to successfully develop products and expand our business depends on many factors, including our ability to meet working capital needs, the availability of equity or debt financing and, over time, our ability to generate cash flows from operations.
Sources and Uses of Capital Since inception, we have financed our operations primarily through equity and debt financing. Our ability to successfully develop products and expand our business depends on many factors, including our ability to meet working capital needs, the availability of equity or debt financing and, over time, our ability to generate cash flows from operations.
As of December 31, 2024, LanzaTech’s outstanding debt comprised the Convertible Note, the Brookfield SAFE, the FPA Put Option liability and the Fixed Maturity Consideration, which are all classified as liabilities for accounting purposes, on its consolidated balance sheets as of December 31, 2024.
As of December 31, 2025, our outstanding debt comprised the Brookfield Loan, the FPA Put Option liability and the Fixed Maturity Consideration, which are all classified as liabilities for accounting purposes, on our consolidated balance sheets as of December 31, 2025.
Cash Flows from Financing Activities In the year ended December 31, 2024, net cash from financing activities was $30.2 million , compared to net cash provided by financing activities of $148.2 million in the year ended December 31, 2023.
Cash Flows from Financing Activities Net cash from financing activities was $25.6 million for the year ended December 31, 2025, compared to net cash provided by financing activities of $30.2 million for the year ended December 31, 2024.
Our net losses after tax were $137.7 million for the year ended December 31, 2024 and $134.1 million for the prior year. As of December 31, 2024 we had accumulated deficit of $969.6 million compared to an accumulated deficit of $831.9 million as of December 31, 2023.
Our net losses after tax were $49.0 million and $137.7 million for the year ended December 31, 2025 and 2024, respectively. As of December 31, 2025 we had an accumulated deficit of $1,018.6 million compared to an accumulated deficit of $969.6 million as of December 31, 2024.
References to “AMCI” refer to AMCI Acquisition Corp. II prior to the Business Combination. This discussion contains forward-looking statements that involve risks and uncertainties about our business and operations. Our actual results could differ materially from those discussed in the forward-looking statements.
This discussion contains forward-looking statements that involve risks and uncertainties about our business and operations. Our actual results could differ materially from those discussed in the forward-looking statements.
Cash Flows Provided by Investing Activities In the year ended December 31, 2024, net cash provided by investing activities was $28.4 million, compared to net cash used by investing activities of $(57.9) million in the year ended December 31, 2023.
Cash Flows Provided by Investing Activities Net cash provided by investing activities was $11.2 million for the year ended December 31, 2025, compared to $28.4 million of net cash provided by investing activities for the year ended December 31, 2024.
Recently Issued and Adopted Accounting Standards See Note 2 to our consolidated financial statements for a description of recent accounting pronouncements, including the actual and expected dates of adoption and estimate effects on our consolidated results of operations and financial condition, which is incorporated herein by reference.
Recently Issued and Adopted Accounting Standards See Note 2 to our consolidated financial statements for a description of recent accounting pronouncements, including the actual and expected dates of adoption and estimate effects on our consolidated results of operations and financial condition, which is incorporated herein by reference. 74 Non-GAAP Financial Measures To supplement our financial statements presented in accordance with GAAP and to provide investors with additional information regarding our financial results, we have presented Adjusted EBITDA, a non-GAAP financial measure.
(4) Adjusted EBITDA, a non-GAAP financial measure, is calculated as net loss, excluding the impact of depreciation, interest income, net, stock-based compensation, change in fair value of warrant liabilities, change in fair value of SAFE liabilities, change in fair value of the FPA Put Option liability and Fixed Maturity Consideration, change in fair value of the Convertible Note and associated transaction costs, transaction costs on issuance of FPA, loss from equity method investees, net and other one-time costs related to the Business Combination and securities registration on Form S-4, our registration statement on Form S-1, and non-recurring regulatory matters.
(4) Adjusted EBITDA, a non-GAAP financial measure, is calculated as net loss, excluding the impact of depreciation, interest income, net, stock-based compensation expense, change in fair value of warrant liabilities, loss on the Brookfield SAFE extinguishment, change in fair value of the Brookfield SAFE and the Brookfield Loan liabilities, change in fair value of the FPA Put Option liability and Fixed Maturity Consideration (net of interest accretion reversal), change in fair value of the Convertible Note, change in fair value of the PIPE Warrant and loss from equity method investees, net.
The following table reconciles Adjusted EBITDA to net loss, the most directly comparable financial measure calculated and presented in accordance with GAAP: Reconciliation of Net Loss to Adjusted EBITDA Years Ended December 31, (In thousands) 2024 2023 Net Loss $ (137,731) $ (134,098) Depreciation 5,567 5,452 Interest income, net (3,162) (4,572) Stock-based compensation expense and change in fair value of SAFE and warrant liabilities (1) (4,679) 728 Change in fair value of the FPA Put Option and Fixed Maturity Consideration liabilities (net of interest accretion reversal) 23,283 44,300 Change in fair value of Convertible Note and related transaction costs 14,276 — Transaction costs on issuance of FPA — 451 Loss from equity method investees, net 14,234 2,902 One-time costs related to the Business Combination, initial securities registration and non-recurring regulatory matters (2) — 4,693 Adjusted EBITDA $ (88,212) $ (80,144) __________________ (1) Stock-based compensation expense represents expense related to equity compensation plans.
The following table reconciles Adjusted EBITDA to net loss, the most directly comparable financial measure calculated and presented in accordance with GAAP: 75 Reconciliation of Net Loss to Adjusted EBITDA Years Ended December 31, (In thousands) 2025 2024 Net loss $ (48,951) $ (137,731) Depreciation 4,227 5,567 Interest income, net (1,214) (3,162) Stock-based compensation expense and change in fair value of Brookfield SAFE and warrant liabilities (1) 3,732 (4,679) Loss on Brookfield SAFE extinguishment 6,216 — Change in fair value of the FPA Put Option and Fixed Maturity Consideration liabilities — 23,283 Change in fair value of Convertible Note and related transaction costs (42,980) 14,276 Change in fair value of PIPE Warrant (8,800) — Change in fair value of the Brookfield Loan (net of interest accretion reversal) 5,310 — Change in fair value of the Amended Brookfield Loan (1,400) — Loss from equity method investees, net 12,548 14,234 Adjusted EBITDA $ (71,312) $ (88,212) __________________ (1) Stock-based compensation expense represents expense related to equity compensation plans. 76
Liquidity and Capital Resources Cash and Cash Equivalents Cash and cash equivalents comprise cash on hand, demand deposits at banks, and other short-term, highly liquid investments with original maturity of three months or less that are readily convertible to known amounts of cash and which are subject to an insignificant risk of changes in value.
These increases were partially offset by a loss of $23.4 million due to the increase in fair value of the Brookfield Loan from February 14, 2025 through December 31, 2025 and a loss of $2.5 million due to the increase in fair value of the Brookfield SAFE. 69 Liquidity and Capital Resources Cash and Cash Equivalents Cash and cash equivalents comprise cash on hand, demand deposits at banks, and other short-term, highly liquid investments with original maturity of three months or less that are readily convertible to known amounts of cash and which are subject to an insignificant risk of changes in value.
We define Adjusted EBITDA as our net loss, excluding the impact of depreciation, interest income, net, stock-based compensation, change in fair value of warrant liabilities, change in fair value of SAFE liabilities, change in fair value of the FPA Put Option liability and Fixed Maturity Consideration, change in fair value of the Convertible Note and associated transaction costs, transaction costs on issuance of FPA, loss from equity method investees, net and other one-time costs related to the Business Combination and securities registration on Form S-4, our registration statement on Form S-1, and non-recurring regulatory matters.
We define Adjusted EBITDA as our net loss, excluding the impact of depreciation, interest income, net, stock-based compensation expense, change in fair value of warrant liabilities, loss on the Brookfield SAFE extinguishment, change in fair value of the Brookfield SAFE and the Brookfield Loan liabilities (net of interest accretion reversal), change in fair value of the FPA Put Option liability and Fixed Maturity Consideration, change in fair value of the Convertible Note, change in fair value of the PIPE Warrant and loss from equity method investees, net.
Depreciation) (3) 25,970 44,979 (19,009) (42) % Selling, general & administrative 49,981 50,438 (457) (1) % Adjusted EBITDA (4) $ (88,212) $ (80,144) $ (8,068) 10 % __________________ (1) One-time revenue includes all other revenue other than licensing and sales of microbes and media (2) Includes revenue from licensing and sales of microbes and media.
Depreciation) (3) 30,544 25,970 4,574 18 % Selling, general & administrative expense 47,046 49,981 (2,935) (6) % Adjusted EBITDA (4) $ (71,312) $ (88,212) $ 16,900 19 % __________________ (1) One-time revenue includes all other revenue other than licensing and sales of microbes and media. (2) Includes revenue from licensing and sales of microbes and media.
Non-GAAP Financial Measures To supplement our financial statements presented in accordance with GAAP and to provide investors with additional information regarding our financial results, we have presented Adjusted EBITDA, a non-GAAP financial measure. Adjusted EBITDA is not based on any standardized methodology prescribed by GAAP and is not necessarily comparable to similarly titled measures presented by other companies.
Adjusted EBITDA is not based on any standardized methodology prescribed by GAAP and is not necessarily comparable to similarly titled measures presented by other companies.
This model incorporates transaction details such as stock price, contractual terms, conversions scenarios, dividend yield, risk-free rate, adjusted equity volatility, credit rating, market credit spread, and estimated yield. We regularly reassess our estimates and assumptions as new information becomes available. Any changes in these estimates are reflected in our financial statements in the period in which they occur.
This model incorporates transaction details such as stock price, contractual terms, conversions scenarios, dividend yield, risk-free rate, adjusted equity volatility, credit rating, market credit spread, and estimated yield.
The decrease was offset by the proceeds from the maturity of certain debt securities and the issuance of the Convertible Note. 65 Debt Security Investments Debt security investments comprise mainly held-to-maturity U.S. Treasury and high quality corporate securities that the Company has both the ability and intent to hold to maturity.
Debt Security Investments Debt security investments comprise mainly held-to-maturity U.S. Treasury and high-quality corporate securities that the Company has both the ability and intent to hold to maturity. As of December 31, 2025, held-to-maturity security investments all matured, compared to $12.4 million as of December 31, 2024.
The sensitivity of the fair value calculation to these methods, assumptions, and estimates included could create materially different results under different conditions or using different assumptions.
The sensitivity of the fair value calculation to these method, assumptions, and estimates included could create materially different results under different conditions or using different assumptions. Series A Convertible Senior Preferred Stock – Mezzanine Equity On May 7, 2025, the Company issued Series A Convertible Senior Preferred Stock pursuant to the Preferred Stock Purchase Agreement.
We had cash and cash equivalents of $43.5 million, short-term held-to-maturity debt securities of $12.4 million and an accumulated deficit of $(969.6) million as of December 31, 2024, along with cash outflows from operations of $(89.1) million and net loss of $(137.7) million for the year ended December 31, 2024.
We had cash and cash equivalents of $13.2 million and an accumulated deficit of $(1,018.6) million as of December 31, 2025, along with cash outflows from operations of $(64.9) million and net loss of $(49.0) million for the year ended December 31, 2025.
This was primarily attributable to interest earned on lower cash balances held in savings and money market accounts.
This was primarily attributable to interest earned on lower cash balances held in savings and money market accounts. Other Income, net Other income, net increased $59.3 million in the year ended December 31, 2025 compared to the same period in the prior year.
The consolidated financial statements for the year ended December 31, 2024 included in this Annual Report do not include any adjustments related to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of this uncertainty Cash Flows The following table provides a summary of our cash flows for the years ended December 31, 2024 and December 31, 2023: 68 Years Ended December 31, (in thousands) 2024 2023 Net cash used in operating activities $ (89,060) $ (97,296) Net cash provided by/(used in) investing activities 28,352 (57,911) Net cash provided by financing activities 30,213 148,185 Effects of currency translation on cash, cash equivalents and restricted cash (52) (404) Net decrease in cash, cash equivalents and restricted cash $ (30,547) $ (7,426) Cash Flows Used in Operating Activities Cash flows used in operating activities decreased $8.2 million, or 8%, in the year ended December 31, 2024 compared to the year ended December 31, 2023.
Cash Flows The following table provides a summary of our cash flows for the years ended December 31, 2025 and 2024: Years Ended December 31, (in thousands) 2025 2024 Net cash used in operating activities $ (64,854) $ (89,060) Net cash provided by investing activities 11,150 28,352 Net cash provided by financing activities 25,619 30,213 Effects of currency translation on cash, cash equivalents and restricted cash (601) (52) Net decrease in cash, cash equivalents and restricted cash $ (28,686) $ (30,547) Cash Flows Used in Operating Activities Net cash used in operating activities decreased $24.2 million, or 27.2%, for the year ended December 31, 2025 compared to the year ended December 31, 2024.
Key Financial Metrics: The key elements of LanzaTech’s performance for the years ended December 31, 2024 and December 31, 2023 are summarized in the tables below: Years Ended December 31, (In thousands, except for percentages) 2024 2023 Variance % Change GAAP Measures: Revenue $ 49,592 $ 62,631 $ (13,039) (21) % Net Loss (137,731) (134,098) (3,633) 3 % Key Performance Indicators: One-Time Revenue (1) 37,868 57,754 (19,886) (34) % Recurring Revenue (2) 11,724 4,877 6,847 140 % Total Revenue 49,592 62,631 (13,039) (21) % Cost of Revenues (ex.
See Note 2 — Summary of Significant Accounting Policies of our consolidated financial statements for a full description of our basis of presentation. 66 Key Financial Metrics The key elements of the Company’s performance for the years ended December 31, 2025 and 2024 are summarized in the tables below: Years Ended December 31, (In thousands, except for percentages) 2025 2024 Variance % Change GAAP Measures: Revenue $ 55,845 $ 49,592 $ 6,253 13 % Net income (loss) (48,951) (137,731) 88,780 64 % Key Performance Indicators: One-Time Revenue (1) 34,891 37,868 (2,977) (8) % Recurring Revenue (2) 20,954 11,724 9,230 79 % Total Revenue 55,845 49,592 6,253 13 % Cost of Revenues (ex.
See Note 2 - Summary of Significant Accounting Policies to our consolidated financial statements for a full description of our basis of presentation.
For a description of these investments see Note 2 — Summary of Significant Accounting Policies, Note 7 – Brookfield Investments and Note 9 – Forward Purchase Agreement in our consolidated financial statements for further information.
Selling, general and administrative expense SG&A expense decreased $0.5 million, or 1%, in the year ended December 31, 2024, compared to the prior year .
Selling, general and administrative expense SG&A expense decreased $2.9 million, or 5.9%, in the year ended December 31, 2025, compared to the same period in the prior year. The decrease was primarily attributable to a $9.6 million reduction in personnel and contractor expenses, driven by headcount reductions during the year and a decline of $1.0 million in facilities-related expenses.
Research and Development R&D expense increased $8.9 million, or 13%, in the year ended December 31, 2024, compared to the prior year, primarily due to an increase of $10.5 million in external R&D services related to project development costs that are not currently eligible for capitalization nor tied to revenue agreements.
Research and Development R&D expense decreased $23.8 million, or 30.9%, in the year ended December 31, 2025, compared to the same period in the prior year. The decrease was primarily driven by an $11.2 million reduction in external R&D services expenses related to project development costs.
However, because certain of the actions described above are subject to market and other conditions not within the Company’s control, management has concluded that these plans do not alleviate substantial doubt about our ability to continue as a going concern.
Management has concluded that the financing transactions completed in 2025 and in January 2026 and our additional plans to raise additional capital, which remain subject to uncertainty, do not alleviate substantial doubt about our ability to continue as a going concern.
Engineering and other services revenue decreased by $19.4 million, mainly due to a reduction of $28.8 million in revenue from projects with existing customers, which includes a decrease of $19.6 million from three large projects.
The increase was partially offset by a $3.8 million reduction in JDA revenue reflecting project completions and the absence of new contracts following workforce reductions. The increase was also partially offset by a $3.6 million decrease in engineering and other services revenue primarily due to the completion of projects with existing customers and a decrease in revenue from new customers.
The following table shows the balances of our cash, cash equivalents and restricted cash as of December 31, 2024 and December 31, 2023: Years Ended December 31, (In thousands, except for percentages) 2024 2023 Variance % Change Total cash, cash equivalents, and restricted cash $ 45,737 $ 76,284 $ (30,547) (40) % As of December 31, 2024, compared to December 31, 2023, LanzaTech’s cash, cash equivalents, and restricted cash decreased by $30.5 million, or 40%, primarily due to funding the net loss adjusted for non-cash charges (see cash flow section below) and purchases of property, plant and equipment.
The following table shows the balances of our cash, cash equivalents and restricted cash as of December 31, 2025 and December 31, 2024: December 31, December 31, (In thousands, except for percentages) 2025 2024 Variance % Change Total cash, cash equivalents, and restricted cash $ 17,051 $ 45,737 $ (28,686) (62.7) % As of December 31, 2025, compared to December 31, 2024, LanzaTech’s cash, cash equivalents, and restricted cash decreased by $28.7 million , or 62.7% , primarily due to losses from operations and the partial settlement of the Brookfield Loan, partially offset by proceeds from maturity of debt securities held for investment, and preferred stock issuance.
These decreases were offset by an increase of $0.4 million for facilities and consumable expenses compared to the prior year . Interest income, net Interest income, net decreased $1.4 million in the year ended December 31, 2024 compared to the prior year .
The decrease was partially offset by a $7.7 million increase in professional fees associated with the Company’s restructuring efforts and initiatives to realign business priorities. Interest income, net Interest income, net decreased $1.9 million in the year ended December 31, 2025 compared to the same period in the prior year.